Developer of novel pharmaceutical products designed to treat disorders of the urogenital tract. The company's products include selective serotonin, reuptake inhibitor and mixed serotonin agonist-antagonist, enabling patients to have improved urinary continence.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Later Stage VC (Series A) | 27-Jul-2018 | $2.32M | 000.00 | 0000 | Completed | Generating Revenue |
2. Early Stage VC | 27-May-2016 | 00.00 | 000.00 | Completed | Generating Revenue | |
1. Debt - General | $3.16M | $3.16M | Completed | Startup |
Name | Representing | Role | Since |
---|---|---|---|
Benedikt Timmerman Ph.D | Self | Board Member | 000 0000 |
Christian Chavy | Ixaltis | Chairman | 000 0000 |
Hasnaa Hafid | iXO Private Equity | Board Observer | 000 0000 |
Jean-Michel Petit | Institut Régional de Développement Industriel | Board Member | 000 0000 |
Mario Caria | Sofimac Investment Managers | Board Member | 000 0000 |
Growth Rate
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Emergence (Incubation) | Asset Manager | Minority | 000 0000 | 000000 0 | |
UROsphere | Corporation | Minority | 000 0000 | 000000 0 | |
Institut Régional de Développement Industriel | Venture Capital | Minority | 000 0000 | 000000 0 | |
iXO Private Equity | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Pierre Olivier Goineau | Angel (individual) | Minority | 000 0000 | 000000 0 |
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000 (00000 0000 | 30-May-2016 | 000000000 00000 00 | Buildings and Property | 0000000 0000000 00 |